<!DOCTYPE html>
<html lang="" xml:lang="">
<head>

  <meta charset="utf-8" />
  <meta http-equiv="X-UA-Compatible" content="IE=edge" />
  <title>2 The HIV/AIDS epidemic | Bayesian spatio-temporal methods for small-area estimation of HIV indicators</title>
  <meta name="description" content="2 The HIV/AIDS epidemic | Bayesian spatio-temporal methods for small-area estimation of HIV indicators" />
  <meta name="generator" content="bookdown 0.26 and GitBook 2.6.7" />

  <meta property="og:title" content="2 The HIV/AIDS epidemic | Bayesian spatio-temporal methods for small-area estimation of HIV indicators" />
  <meta property="og:type" content="book" />
  
  
  

  <meta name="twitter:card" content="summary" />
  <meta name="twitter:title" content="2 The HIV/AIDS epidemic | Bayesian spatio-temporal methods for small-area estimation of HIV indicators" />
  
  
  

<meta name="author" content="Adam Howes" />



  <meta name="viewport" content="width=device-width, initial-scale=1" />
  <meta name="apple-mobile-web-app-capable" content="yes" />
  <meta name="apple-mobile-web-app-status-bar-style" content="black" />
  
  
<link rel="prev" href="introduction.html"/>
<link rel="next" href="bayes-st.html"/>
<style type="text/css">
p.abstract{
  text-align: center;
  font-weight: bold;
}
div.abstract{
  margin: auto;
  width: 90%;
}
</style>
<script src="libs/jquery-3.6.0/jquery-3.6.0.min.js"></script>
<script src="https://cdn.jsdelivr.net/npm/fuse.js@6.4.6/dist/fuse.min.js"></script>
<link href="libs/gitbook-2.6.7/css/style.css" rel="stylesheet" />
<link href="libs/gitbook-2.6.7/css/plugin-table.css" rel="stylesheet" />
<link href="libs/gitbook-2.6.7/css/plugin-bookdown.css" rel="stylesheet" />
<link href="libs/gitbook-2.6.7/css/plugin-highlight.css" rel="stylesheet" />
<link href="libs/gitbook-2.6.7/css/plugin-search.css" rel="stylesheet" />
<link href="libs/gitbook-2.6.7/css/plugin-fontsettings.css" rel="stylesheet" />
<link href="libs/gitbook-2.6.7/css/plugin-clipboard.css" rel="stylesheet" />








<link href="libs/anchor-sections-1.1.0/anchor-sections.css" rel="stylesheet" />
<link href="libs/anchor-sections-1.1.0/anchor-sections-hash.css" rel="stylesheet" />
<script src="libs/anchor-sections-1.1.0/anchor-sections.js"></script>


<style type="text/css">
pre > code.sourceCode { white-space: pre; position: relative; }
pre > code.sourceCode > span { display: inline-block; line-height: 1.25; }
pre > code.sourceCode > span:empty { height: 1.2em; }
.sourceCode { overflow: visible; }
code.sourceCode > span { color: inherit; text-decoration: inherit; }
pre.sourceCode { margin: 0; }
@media screen {
div.sourceCode { overflow: auto; }
}
@media print {
pre > code.sourceCode { white-space: pre-wrap; }
pre > code.sourceCode > span { text-indent: -5em; padding-left: 5em; }
}
pre.numberSource code
  { counter-reset: source-line 0; }
pre.numberSource code > span
  { position: relative; left: -4em; counter-increment: source-line; }
pre.numberSource code > span > a:first-child::before
  { content: counter(source-line);
    position: relative; left: -1em; text-align: right; vertical-align: baseline;
    border: none; display: inline-block;
    -webkit-touch-callout: none; -webkit-user-select: none;
    -khtml-user-select: none; -moz-user-select: none;
    -ms-user-select: none; user-select: none;
    padding: 0 4px; width: 4em;
    color: #aaaaaa;
  }
pre.numberSource { margin-left: 3em; border-left: 1px solid #aaaaaa;  padding-left: 4px; }
div.sourceCode
  {   }
@media screen {
pre > code.sourceCode > span > a:first-child::before { text-decoration: underline; }
}
code span.al { color: #ff0000; font-weight: bold; } /* Alert */
code span.an { color: #60a0b0; font-weight: bold; font-style: italic; } /* Annotation */
code span.at { color: #7d9029; } /* Attribute */
code span.bn { color: #40a070; } /* BaseN */
code span.bu { color: #008000; } /* BuiltIn */
code span.cf { color: #007020; font-weight: bold; } /* ControlFlow */
code span.ch { color: #4070a0; } /* Char */
code span.cn { color: #880000; } /* Constant */
code span.co { color: #60a0b0; font-style: italic; } /* Comment */
code span.cv { color: #60a0b0; font-weight: bold; font-style: italic; } /* CommentVar */
code span.do { color: #ba2121; font-style: italic; } /* Documentation */
code span.dt { color: #902000; } /* DataType */
code span.dv { color: #40a070; } /* DecVal */
code span.er { color: #ff0000; font-weight: bold; } /* Error */
code span.ex { } /* Extension */
code span.fl { color: #40a070; } /* Float */
code span.fu { color: #06287e; } /* Function */
code span.im { color: #008000; font-weight: bold; } /* Import */
code span.in { color: #60a0b0; font-weight: bold; font-style: italic; } /* Information */
code span.kw { color: #007020; font-weight: bold; } /* Keyword */
code span.op { color: #666666; } /* Operator */
code span.ot { color: #007020; } /* Other */
code span.pp { color: #bc7a00; } /* Preprocessor */
code span.sc { color: #4070a0; } /* SpecialChar */
code span.ss { color: #bb6688; } /* SpecialString */
code span.st { color: #4070a0; } /* String */
code span.va { color: #19177c; } /* Variable */
code span.vs { color: #4070a0; } /* VerbatimString */
code span.wa { color: #60a0b0; font-weight: bold; font-style: italic; } /* Warning */
</style>

<style type="text/css">
/* Used with Pandoc 2.11+ new --citeproc when CSL is used */
div.csl-bib-body { }
div.csl-entry {
  clear: both;
}
.hanging div.csl-entry {
  margin-left:2em;
  text-indent:-2em;
}
div.csl-left-margin {
  min-width:2em;
  float:left;
}
div.csl-right-inline {
  margin-left:2em;
  padding-left:1em;
}
div.csl-indent {
  margin-left: 2em;
}
</style>

<link rel="stylesheet" href="templates/style.css" type="text/css" />
</head>

<body>



  <div class="book without-animation with-summary font-size-2 font-family-1" data-basepath=".">

    <div class="book-summary">
      <nav role="navigation">

<ul class="summary">
<li class="chapter" data-level="" data-path="index.html"><a href="index.html"><i class="fa fa-check"></i>Welcome</a>
<ul>
<li class="chapter" data-level="" data-path="index.html"><a href="index.html#acknowledgments"><i class="fa fa-check"></i>Acknowledgments</a></li>
<li class="chapter" data-level="" data-path="index.html"><a href="index.html#abbreviations"><i class="fa fa-check"></i>Abbreviations</a></li>
<li class="chapter" data-level="" data-path="index.html"><a href="index.html#notations"><i class="fa fa-check"></i>Notations</a></li>
</ul></li>
<li class="chapter" data-level="1" data-path="introduction.html"><a href="introduction.html"><i class="fa fa-check"></i><b>1</b> Introduction</a>
<ul>
<li class="chapter" data-level="1.1" data-path="introduction.html"><a href="introduction.html#chapter-overview"><i class="fa fa-check"></i><b>1.1</b> Chapter overview</a></li>
</ul></li>
<li class="chapter" data-level="2" data-path="hiv-aids.html"><a href="hiv-aids.html"><i class="fa fa-check"></i><b>2</b> The HIV/AIDS epidemic</a>
<ul>
<li class="chapter" data-level="2.1" data-path="hiv-aids.html"><a href="hiv-aids.html#background"><i class="fa fa-check"></i><b>2.1</b> Background</a></li>
<li class="chapter" data-level="2.2" data-path="hiv-aids.html"><a href="hiv-aids.html#surveillance"><i class="fa fa-check"></i><b>2.2</b> HIV surveillance</a>
<ul>
<li class="chapter" data-level="2.2.1" data-path="hiv-aids.html"><a href="hiv-aids.html#hiv-data"><i class="fa fa-check"></i><b>2.2.1</b> Data</a></li>
<li class="chapter" data-level="2.2.2" data-path="hiv-aids.html"><a href="hiv-aids.html#challenges"><i class="fa fa-check"></i><b>2.2.2</b> Challenges</a></li>
<li class="chapter" data-level="2.2.3" data-path="hiv-aids.html"><a href="hiv-aids.html#statistical-approaches"><i class="fa fa-check"></i><b>2.2.3</b> Statistical approaches</a></li>
</ul></li>
</ul></li>
<li class="chapter" data-level="3" data-path="bayes-st.html"><a href="bayes-st.html"><i class="fa fa-check"></i><b>3</b> Bayesian spatio-temporal statistics</a>
<ul>
<li class="chapter" data-level="3.1" data-path="bayes-st.html"><a href="bayes-st.html#bayesian-statistics"><i class="fa fa-check"></i><b>3.1</b> Bayesian statistics</a>
<ul>
<li class="chapter" data-level="3.1.1" data-path="bayes-st.html"><a href="bayes-st.html#bayesian-modelling"><i class="fa fa-check"></i><b>3.1.1</b> Bayesian modelling</a></li>
<li class="chapter" data-level="3.1.2" data-path="bayes-st.html"><a href="bayes-st.html#bayesian-computation"><i class="fa fa-check"></i><b>3.1.2</b> Bayesian computation</a></li>
<li class="chapter" data-level="3.1.3" data-path="bayes-st.html"><a href="bayes-st.html#interplay-between-modelling-and-computation"><i class="fa fa-check"></i><b>3.1.3</b> Interplay between modelling and computation</a></li>
</ul></li>
<li class="chapter" data-level="3.2" data-path="bayes-st.html"><a href="bayes-st.html#st-statistics"><i class="fa fa-check"></i><b>3.2</b> Spatio-temporal statistics</a>
<ul>
<li class="chapter" data-level="3.2.1" data-path="bayes-st.html"><a href="bayes-st.html#properties"><i class="fa fa-check"></i><b>3.2.1</b> Properties of spatio-temporal data</a></li>
<li class="chapter" data-level="3.2.2" data-path="bayes-st.html"><a href="bayes-st.html#small-area-estimation"><i class="fa fa-check"></i><b>3.2.2</b> Small-area estimation</a></li>
</ul></li>
<li class="chapter" data-level="3.3" data-path="bayes-st.html"><a href="bayes-st.html#model-structure"><i class="fa fa-check"></i><b>3.3</b> Model structure</a>
<ul>
<li class="chapter" data-level="3.3.1" data-path="bayes-st.html"><a href="bayes-st.html#linear-model"><i class="fa fa-check"></i><b>3.3.1</b> Linear model</a></li>
<li class="chapter" data-level="3.3.2" data-path="bayes-st.html"><a href="bayes-st.html#generalised-linear-model"><i class="fa fa-check"></i><b>3.3.2</b> Generalised linear model</a></li>
<li class="chapter" data-level="3.3.3" data-path="bayes-st.html"><a href="bayes-st.html#generalised-linear-mixed-effects-model"><i class="fa fa-check"></i><b>3.3.3</b> Generalised linear mixed effects model</a></li>
<li class="chapter" data-level="3.3.4" data-path="bayes-st.html"><a href="bayes-st.html#lgm"><i class="fa fa-check"></i><b>3.3.4</b> Latent Gaussian model</a></li>
<li class="chapter" data-level="3.3.5" data-path="bayes-st.html"><a href="bayes-st.html#elgm"><i class="fa fa-check"></i><b>3.3.5</b> Extended latent Gaussian model</a></li>
</ul></li>
<li class="chapter" data-level="3.4" data-path="bayes-st.html"><a href="bayes-st.html#model-comparison"><i class="fa fa-check"></i><b>3.4</b> Model comparison</a>
<ul>
<li class="chapter" data-level="3.4.1" data-path="bayes-st.html"><a href="bayes-st.html#bayes-factors"><i class="fa fa-check"></i><b>3.4.1</b> Bayes factors</a></li>
<li class="chapter" data-level="3.4.2" data-path="bayes-st.html"><a href="bayes-st.html#information-criteria"><i class="fa fa-check"></i><b>3.4.2</b> Information criteria</a></li>
<li class="chapter" data-level="3.4.3" data-path="bayes-st.html"><a href="bayes-st.html#cross-validation"><i class="fa fa-check"></i><b>3.4.3</b> Cross-validation</a></li>
<li class="chapter" data-level="3.4.4" data-path="bayes-st.html"><a href="bayes-st.html#scoring-rules"><i class="fa fa-check"></i><b>3.4.4</b> Scoring rules</a></li>
</ul></li>
<li class="chapter" data-level="3.5" data-path="bayes-st.html"><a href="bayes-st.html#survey"><i class="fa fa-check"></i><b>3.5</b> Survey methods</a>
<ul>
<li class="chapter" data-level="3.5.1" data-path="bayes-st.html"><a href="bayes-st.html#survey-notation-and-key-terms"><i class="fa fa-check"></i><b>3.5.1</b> Survey notation and key terms</a></li>
<li class="chapter" data-level="3.5.2" data-path="bayes-st.html"><a href="bayes-st.html#survey-design"><i class="fa fa-check"></i><b>3.5.2</b> Survey design</a></li>
<li class="chapter" data-level="3.5.3" data-path="bayes-st.html"><a href="bayes-st.html#survey-analysis"><i class="fa fa-check"></i><b>3.5.3</b> Survey analysis</a></li>
</ul></li>
</ul></li>
<li class="chapter" data-level="4" data-path="beyond-borders.html"><a href="beyond-borders.html"><i class="fa fa-check"></i><b>4</b> Models for areal spatial structure</a>
<ul>
<li class="chapter" data-level="4.1" data-path="beyond-borders.html"><a href="beyond-borders.html#adjacency-models"><i class="fa fa-check"></i><b>4.1</b> Models based on adjacency</a>
<ul>
<li class="chapter" data-level="4.1.1" data-path="beyond-borders.html"><a href="beyond-borders.html#besag"><i class="fa fa-check"></i><b>4.1.1</b> The Besag model</a></li>
<li class="chapter" data-level="4.1.2" data-path="beyond-borders.html"><a href="beyond-borders.html#best-practises-for-the-besag-model"><i class="fa fa-check"></i><b>4.1.2</b> Best practises for the Besag model</a></li>
<li class="chapter" data-level="4.1.3" data-path="beyond-borders.html"><a href="beyond-borders.html#concerns"><i class="fa fa-check"></i><b>4.1.3</b> Concerns about the Besag model</a></li>
<li class="chapter" data-level="4.1.4" data-path="beyond-borders.html"><a href="beyond-borders.html#weighted-icar-models"><i class="fa fa-check"></i><b>4.1.4</b> Weighted ICAR models</a></li>
<li class="chapter" data-level="4.1.5" data-path="beyond-borders.html"><a href="beyond-borders.html#bym2"><i class="fa fa-check"></i><b>4.1.5</b> The reparameterised Besag-York-Mollié model</a></li>
</ul></li>
<li class="chapter" data-level="4.2" data-path="beyond-borders.html"><a href="beyond-borders.html#kernel-models"><i class="fa fa-check"></i><b>4.2</b> Models using kernels</a>
<ul>
<li class="chapter" data-level="4.2.1" data-path="beyond-borders.html"><a href="beyond-borders.html#centroid-kernel"><i class="fa fa-check"></i><b>4.2.1</b> Centroid kernel</a></li>
<li class="chapter" data-level="4.2.2" data-path="beyond-borders.html"><a href="beyond-borders.html#integrated-kernel"><i class="fa fa-check"></i><b>4.2.2</b> Integrated kernel</a></li>
</ul></li>
<li class="chapter" data-level="4.3" data-path="beyond-borders.html"><a href="beyond-borders.html#simulation-study"><i class="fa fa-check"></i><b>4.3</b> Simulation study</a>
<ul>
<li class="chapter" data-level="4.3.1" data-path="beyond-borders.html"><a href="beyond-borders.html#synthetic-data"><i class="fa fa-check"></i><b>4.3.1</b> Synthetic data</a></li>
<li class="chapter" data-level="4.3.2" data-path="beyond-borders.html"><a href="beyond-borders.html#inferential-models"><i class="fa fa-check"></i><b>4.3.2</b> Inferential models</a></li>
<li class="chapter" data-level="4.3.3" data-path="beyond-borders.html"><a href="beyond-borders.html#model-assessment"><i class="fa fa-check"></i><b>4.3.3</b> Model assessment</a></li>
<li class="chapter" data-level="4.3.4" data-path="beyond-borders.html"><a href="beyond-borders.html#results"><i class="fa fa-check"></i><b>4.3.4</b> Results</a></li>
</ul></li>
<li class="chapter" data-level="4.4" data-path="beyond-borders.html"><a href="beyond-borders.html#hiv-study"><i class="fa fa-check"></i><b>4.4</b> HIV prevalence study</a>
<ul>
<li class="chapter" data-level="4.4.1" data-path="beyond-borders.html"><a href="beyond-borders.html#household-survey-data"><i class="fa fa-check"></i><b>4.4.1</b> Household survey data</a></li>
<li class="chapter" data-level="4.4.2" data-path="beyond-borders.html"><a href="beyond-borders.html#inferential-models-1"><i class="fa fa-check"></i><b>4.4.2</b> Inferential models</a></li>
<li class="chapter" data-level="4.4.3" data-path="beyond-borders.html"><a href="beyond-borders.html#model-comparison-1"><i class="fa fa-check"></i><b>4.4.3</b> Model comparison</a></li>
<li class="chapter" data-level="4.4.4" data-path="beyond-borders.html"><a href="beyond-borders.html#results-1"><i class="fa fa-check"></i><b>4.4.4</b> Results</a></li>
</ul></li>
<li class="chapter" data-level="4.5" data-path="beyond-borders.html"><a href="beyond-borders.html#discussion"><i class="fa fa-check"></i><b>4.5</b> Discussion</a>
<ul>
<li class="chapter" data-level="4.5.1" data-path="beyond-borders.html"><a href="beyond-borders.html#modelling"><i class="fa fa-check"></i><b>4.5.1</b> Modelling</a></li>
<li class="chapter" data-level="4.5.2" data-path="beyond-borders.html"><a href="beyond-borders.html#model-selection"><i class="fa fa-check"></i><b>4.5.2</b> Model selection</a></li>
<li class="chapter" data-level="4.5.3" data-path="beyond-borders.html"><a href="beyond-borders.html#inference-1"><i class="fa fa-check"></i><b>4.5.3</b> Inference</a></li>
</ul></li>
</ul></li>
<li class="chapter" data-level="5" data-path="multi-agyw.html"><a href="multi-agyw.html"><i class="fa fa-check"></i><b>5</b> A model for risk group proportions</a>
<ul>
<li class="chapter" data-level="5.1" data-path="multi-agyw.html"><a href="multi-agyw.html#background-1"><i class="fa fa-check"></i><b>5.1</b> Background</a></li>
<li class="chapter" data-level="5.2" data-path="multi-agyw.html"><a href="multi-agyw.html#data"><i class="fa fa-check"></i><b>5.2</b> Data</a>
<ul>
<li class="chapter" data-level="5.2.1" data-path="multi-agyw.html"><a href="multi-agyw.html#behavioural-data-from-household-surveys"><i class="fa fa-check"></i><b>5.2.1</b> Behavioural data from household surveys</a></li>
<li class="chapter" data-level="5.2.2" data-path="multi-agyw.html"><a href="multi-agyw.html#other-data"><i class="fa fa-check"></i><b>5.2.2</b> Other data</a></li>
</ul></li>
<li class="chapter" data-level="5.3" data-path="multi-agyw.html"><a href="multi-agyw.html#model-for-risk-group-proportions"><i class="fa fa-check"></i><b>5.3</b> Model for risk group proportions</a>
<ul>
<li class="chapter" data-level="5.3.1" data-path="multi-agyw.html"><a href="multi-agyw.html#st-multinomial"><i class="fa fa-check"></i><b>5.3.1</b> Spatio-temporal multinomial logistic regression</a></li>
<li class="chapter" data-level="5.3.2" data-path="multi-agyw.html"><a href="multi-agyw.html#s-logistic"><i class="fa fa-check"></i><b>5.3.2</b> Spatial logistic regression</a></li>
<li class="chapter" data-level="5.3.3" data-path="multi-agyw.html"><a href="multi-agyw.html#female-sex-worker-population-size-adjustment"><i class="fa fa-check"></i><b>5.3.3</b> Female sex worker population size adjustment</a></li>
</ul></li>
<li class="chapter" data-level="5.4" data-path="multi-agyw.html"><a href="multi-agyw.html#prevalence-and-incidence-by-risk-group"><i class="fa fa-check"></i><b>5.4</b> Prevalence and incidence by risk group</a>
<ul>
<li class="chapter" data-level="5.4.1" data-path="multi-agyw.html"><a href="multi-agyw.html#disaggregation-of-naomi-prevalence-estimates"><i class="fa fa-check"></i><b>5.4.1</b> Disaggregation of Naomi prevalence estimates</a></li>
<li class="chapter" data-level="5.4.2" data-path="multi-agyw.html"><a href="multi-agyw.html#disaggregation-of-naomi-incidence-estimates"><i class="fa fa-check"></i><b>5.4.2</b> Disaggregation of Naomi incidence estimates</a></li>
<li class="chapter" data-level="5.4.3" data-path="multi-agyw.html"><a href="multi-agyw.html#expected-new-infections-reached"><i class="fa fa-check"></i><b>5.4.3</b> Expected new infections reached</a></li>
</ul></li>
<li class="chapter" data-level="5.5" data-path="multi-agyw.html"><a href="multi-agyw.html#results-2"><i class="fa fa-check"></i><b>5.5</b> Results</a>
<ul>
<li class="chapter" data-level="5.5.1" data-path="multi-agyw.html"><a href="multi-agyw.html#model-for-risk-group-proportions-1"><i class="fa fa-check"></i><b>5.5.1</b> Model for risk group proportions</a></li>
<li class="chapter" data-level="5.5.2" data-path="multi-agyw.html"><a href="multi-agyw.html#prevalence-and-incidence-by-risk-group-1"><i class="fa fa-check"></i><b>5.5.2</b> Prevalence and incidence by risk group</a></li>
</ul></li>
<li class="chapter" data-level="5.6" data-path="multi-agyw.html"><a href="multi-agyw.html#discussion-1"><i class="fa fa-check"></i><b>5.6</b> Discussion</a>
<ul>
<li class="chapter" data-level="5.6.1" data-path="multi-agyw.html"><a href="multi-agyw.html#limitations"><i class="fa fa-check"></i><b>5.6.1</b> Limitations</a></li>
<li class="chapter" data-level="5.6.2" data-path="multi-agyw.html"><a href="multi-agyw.html#conclusion"><i class="fa fa-check"></i><b>5.6.2</b> Conclusion</a></li>
</ul></li>
</ul></li>
<li class="chapter" data-level="6" data-path="naomi-aghq.html"><a href="naomi-aghq.html"><i class="fa fa-check"></i><b>6</b> Fast approximate Bayesian inference</a>
<ul>
<li class="chapter" data-level="6.1" data-path="naomi-aghq.html"><a href="naomi-aghq.html#naomi-inference"><i class="fa fa-check"></i><b>6.1</b> Inference methods and software</a>
<ul>
<li class="chapter" data-level="6.1.1" data-path="naomi-aghq.html"><a href="naomi-aghq.html#la"><i class="fa fa-check"></i><b>6.1.1</b> The Laplace approximation</a></li>
<li class="chapter" data-level="6.1.2" data-path="naomi-aghq.html"><a href="naomi-aghq.html#quadrature"><i class="fa fa-check"></i><b>6.1.2</b> Quadrature</a></li>
<li class="chapter" data-level="6.1.3" data-path="naomi-aghq.html"><a href="naomi-aghq.html#inla"><i class="fa fa-check"></i><b>6.1.3</b> Integrated nested Laplace approximation</a></li>
<li class="chapter" data-level="6.1.4" data-path="naomi-aghq.html"><a href="naomi-aghq.html#software"><i class="fa fa-check"></i><b>6.1.4</b> Software</a></li>
</ul></li>
<li class="chapter" data-level="6.2" data-path="naomi-aghq.html"><a href="naomi-aghq.html#universal"><i class="fa fa-check"></i><b>6.2</b> A universal INLA implementation</a>
<ul>
<li class="chapter" data-level="6.2.1" data-path="naomi-aghq.html"><a href="naomi-aghq.html#epil"><i class="fa fa-check"></i><b>6.2.1</b> Epilepsy GLMM</a></li>
<li class="chapter" data-level="6.2.2" data-path="naomi-aghq.html"><a href="naomi-aghq.html#loaloa"><i class="fa fa-check"></i><b>6.2.2</b> Loa loa ELGM</a></li>
</ul></li>
<li class="chapter" data-level="6.3" data-path="naomi-aghq.html"><a href="naomi-aghq.html#naomi"><i class="fa fa-check"></i><b>6.3</b> The Naomi model</a>
<ul>
<li class="chapter" data-level="6.3.1" data-path="naomi-aghq.html"><a href="naomi-aghq.html#naomi-model"><i class="fa fa-check"></i><b>6.3.1</b> Model structure</a></li>
<li class="chapter" data-level="6.3.2" data-path="naomi-aghq.html"><a href="naomi-aghq.html#naomi-elgm"><i class="fa fa-check"></i><b>6.3.2</b> Naomi as an ELGM</a></li>
</ul></li>
<li class="chapter" data-level="6.4" data-path="naomi-aghq.html"><a href="naomi-aghq.html#pca-aghq"><i class="fa fa-check"></i><b>6.4</b> AGHQ in moderate dimensions</a>
<ul>
<li class="chapter" data-level="6.4.1" data-path="naomi-aghq.html"><a href="naomi-aghq.html#aghq-with-variable-levels"><i class="fa fa-check"></i><b>6.4.1</b> AGHQ with variable levels</a></li>
<li class="chapter" data-level="6.4.2" data-path="naomi-aghq.html"><a href="naomi-aghq.html#principal-components-analysis"><i class="fa fa-check"></i><b>6.4.2</b> Principal components analysis</a></li>
</ul></li>
<li class="chapter" data-level="6.5" data-path="naomi-aghq.html"><a href="naomi-aghq.html#malawi"><i class="fa fa-check"></i><b>6.5</b> Malawi case-study</a>
<ul>
<li class="chapter" data-level="6.5.1" data-path="naomi-aghq.html"><a href="naomi-aghq.html#naomi-nuts"><i class="fa fa-check"></i><b>6.5.1</b> NUTS convergence and suitability</a></li>
<li class="chapter" data-level="6.5.2" data-path="naomi-aghq.html"><a href="naomi-aghq.html#use-of-pca-aghq"><i class="fa fa-check"></i><b>6.5.2</b> Use of PCA-AGHQ</a></li>
<li class="chapter" data-level="6.5.3" data-path="naomi-aghq.html"><a href="naomi-aghq.html#inference-comparison"><i class="fa fa-check"></i><b>6.5.3</b> Inference comparison</a></li>
<li class="chapter" data-level="6.5.4" data-path="naomi-aghq.html"><a href="naomi-aghq.html#exceedance-probabilities"><i class="fa fa-check"></i><b>6.5.4</b> Exceedance probabilities</a></li>
</ul></li>
<li class="chapter" data-level="6.6" data-path="naomi-aghq.html"><a href="naomi-aghq.html#discussion-2"><i class="fa fa-check"></i><b>6.6</b> Discussion</a>
<ul>
<li class="chapter" data-level="6.6.1" data-path="naomi-aghq.html"><a href="naomi-aghq.html#a-universal-inla-implementation"><i class="fa fa-check"></i><b>6.6.1</b> A universal INLA implementation</a></li>
<li class="chapter" data-level="6.6.2" data-path="naomi-aghq.html"><a href="naomi-aghq.html#pca-aghq-with-application-to-inla-for-naomi"><i class="fa fa-check"></i><b>6.6.2</b> PCA-AGHQ with application to INLA for Naomi</a></li>
<li class="chapter" data-level="6.6.3" data-path="naomi-aghq.html"><a href="naomi-aghq.html#suggestions-for-future-work"><i class="fa fa-check"></i><b>6.6.3</b> Suggestions for future work</a></li>
</ul></li>
</ul></li>
<li class="chapter" data-level="7" data-path="conclusions.html"><a href="conclusions.html"><i class="fa fa-check"></i><b>7</b> Conclusions</a>
<ul>
<li class="chapter" data-level="7.1" data-path="conclusions.html"><a href="conclusions.html#contributions"><i class="fa fa-check"></i><b>7.1</b> Contributions</a></li>
<li class="chapter" data-level="7.2" data-path="conclusions.html"><a href="conclusions.html#limitations-1"><i class="fa fa-check"></i><b>7.2</b> Limitations</a></li>
<li class="chapter" data-level="7.3" data-path="conclusions.html"><a href="conclusions.html#future-work"><i class="fa fa-check"></i><b>7.3</b> Future work</a></li>
<li class="chapter" data-level="7.4" data-path="conclusions.html"><a href="conclusions.html#conclusions-1"><i class="fa fa-check"></i><b>7.4</b> Conclusions</a></li>
</ul></li>
<li class="appendix"><span><b>Appendix</b></span></li>
<li class="chapter" data-level="A" data-path="models-for-areal-spatial-structure.html"><a href="models-for-areal-spatial-structure.html"><i class="fa fa-check"></i><b>A</b> Models for areal spatial structure</a>
<ul>
<li class="chapter" data-level="A.1" data-path="models-for-areal-spatial-structure.html"><a href="models-for-areal-spatial-structure.html#aghq-nuts"><i class="fa fa-check"></i><b>A.1</b> Comparison of AGHQ to NUTS</a></li>
<li class="chapter" data-level="A.2" data-path="models-for-areal-spatial-structure.html"><a href="models-for-areal-spatial-structure.html#lengthscale-prior"><i class="fa fa-check"></i><b>A.2</b> Lengthscale prior sensitivity</a></li>
<li class="chapter" data-level="A.3" data-path="models-for-areal-spatial-structure.html"><a href="models-for-areal-spatial-structure.html#simulation-appendix"><i class="fa fa-check"></i><b>A.3</b> Simulation study</a>
<ul>
<li class="chapter" data-level="A.3.1" data-path="models-for-areal-spatial-structure.html"><a href="models-for-areal-spatial-structure.html#lengthscale"><i class="fa fa-check"></i><b>A.3.1</b> Lengthscale hyperparameter recovery</a></li>
<li class="chapter" data-level="A.3.2" data-path="models-for-areal-spatial-structure.html"><a href="models-for-areal-spatial-structure.html#bym2-proportion"><i class="fa fa-check"></i><b>A.3.2</b> BYM2 proportion hyperparameter</a></li>
<li class="chapter" data-level="A.3.3" data-path="models-for-areal-spatial-structure.html"><a href="models-for-areal-spatial-structure.html#mean-squared-error"><i class="fa fa-check"></i><b>A.3.3</b> Mean squared error</a></li>
<li class="chapter" data-level="A.3.4" data-path="models-for-areal-spatial-structure.html"><a href="models-for-areal-spatial-structure.html#continuous-ranked-probability-score"><i class="fa fa-check"></i><b>A.3.4</b> Continuous ranked probability score</a></li>
<li class="chapter" data-level="A.3.5" data-path="models-for-areal-spatial-structure.html"><a href="models-for-areal-spatial-structure.html#calibration"><i class="fa fa-check"></i><b>A.3.5</b> Calibration</a></li>
</ul></li>
<li class="chapter" data-level="A.4" data-path="models-for-areal-spatial-structure.html"><a href="models-for-areal-spatial-structure.html#hiv-appendix"><i class="fa fa-check"></i><b>A.4</b> HIV study</a>
<ul>
<li class="chapter" data-level="A.4.1" data-path="models-for-areal-spatial-structure.html"><a href="models-for-areal-spatial-structure.html#estimates-1"><i class="fa fa-check"></i><b>A.4.1</b> Estimates</a></li>
<li class="chapter" data-level="A.4.2" data-path="models-for-areal-spatial-structure.html"><a href="models-for-areal-spatial-structure.html#cross-validation-1"><i class="fa fa-check"></i><b>A.4.2</b> Cross-validation</a></li>
</ul></li>
</ul></li>
<li class="chapter" data-level="B" data-path="a-model-for-risk-group-proportions.html"><a href="a-model-for-risk-group-proportions.html"><i class="fa fa-check"></i><b>B</b> A model for risk group proportions</a>
<ul>
<li class="chapter" data-level="B.1" data-path="a-model-for-risk-group-proportions.html"><a href="a-model-for-risk-group-proportions.html#the-global-aids-strategy"><i class="fa fa-check"></i><b>B.1</b> The Global AIDS Strategy</a></li>
<li class="chapter" data-level="B.2" data-path="a-model-for-risk-group-proportions.html"><a href="a-model-for-risk-group-proportions.html#household-survey-data-1"><i class="fa fa-check"></i><b>B.2</b> Household survey data</a></li>
<li class="chapter" data-level="B.3" data-path="a-model-for-risk-group-proportions.html"><a href="a-model-for-risk-group-proportions.html#spatial-analysis-levels"><i class="fa fa-check"></i><b>B.3</b> Spatial analysis levels</a></li>
<li class="chapter" data-level="B.4" data-path="a-model-for-risk-group-proportions.html"><a href="a-model-for-risk-group-proportions.html#survey-questions"><i class="fa fa-check"></i><b>B.4</b> Survey questions and risk group allocation</a></li>
<li class="chapter" data-level="B.5" data-path="a-model-for-risk-group-proportions.html"><a href="a-model-for-risk-group-proportions.html#additional-figures"><i class="fa fa-check"></i><b>B.5</b> Additional figures</a></li>
</ul></li>
<li class="chapter" data-level="C" data-path="fast-approximate-bayesian-inference.html"><a href="fast-approximate-bayesian-inference.html"><i class="fa fa-check"></i><b>C</b> Fast approximate Bayesian inference</a>
<ul>
<li class="chapter" data-level="C.1" data-path="fast-approximate-bayesian-inference.html"><a href="fast-approximate-bayesian-inference.html#epilepsy-example"><i class="fa fa-check"></i><b>C.1</b> Epilepsy example</a>
<ul>
<li class="chapter" data-level="C.1.1" data-path="fast-approximate-bayesian-inference.html"><a href="fast-approximate-bayesian-inference.html#tmb-epil"><i class="fa fa-check"></i><b>C.1.1</b> <code>TMB</code> C++ template</a></li>
<li class="chapter" data-level="C.1.2" data-path="fast-approximate-bayesian-inference.html"><a href="fast-approximate-bayesian-inference.html#tmb-modified-epil"><i class="fa fa-check"></i><b>C.1.2</b> Modified <code>TMB</code> C++ template</a></li>
<li class="chapter" data-level="C.1.3" data-path="fast-approximate-bayesian-inference.html"><a href="fast-approximate-bayesian-inference.html#stan-epil"><i class="fa fa-check"></i><b>C.1.3</b> <code>Stan</code> C++ template</a></li>
<li class="chapter" data-level="C.1.4" data-path="fast-approximate-bayesian-inference.html"><a href="fast-approximate-bayesian-inference.html#nuts-convergence-and-suitability"><i class="fa fa-check"></i><b>C.1.4</b> NUTS convergence and suitability</a></li>
</ul></li>
<li class="chapter" data-level="C.2" data-path="fast-approximate-bayesian-inference.html"><a href="fast-approximate-bayesian-inference.html#loa-loa-example"><i class="fa fa-check"></i><b>C.2</b> Loa loa example</a>
<ul>
<li class="chapter" data-level="C.2.1" data-path="fast-approximate-bayesian-inference.html"><a href="fast-approximate-bayesian-inference.html#nuts-convergence-and-suitability-1"><i class="fa fa-check"></i><b>C.2.1</b> NUTS convergence and suitability</a></li>
<li class="chapter" data-level="C.2.2" data-path="fast-approximate-bayesian-inference.html"><a href="fast-approximate-bayesian-inference.html#inference-comparison-1"><i class="fa fa-check"></i><b>C.2.2</b> Inference comparison</a></li>
</ul></li>
<li class="chapter" data-level="C.3" data-path="fast-approximate-bayesian-inference.html"><a href="fast-approximate-bayesian-inference.html#naomi-math"><i class="fa fa-check"></i><b>C.3</b> Simplified Naomi model description</a>
<ul>
<li class="chapter" data-level="C.3.1" data-path="fast-approximate-bayesian-inference.html"><a href="fast-approximate-bayesian-inference.html#naomi-process"><i class="fa fa-check"></i><b>C.3.1</b> Process specification</a></li>
<li class="chapter" data-level="C.3.2" data-path="fast-approximate-bayesian-inference.html"><a href="fast-approximate-bayesian-inference.html#naomi-likelihood"><i class="fa fa-check"></i><b>C.3.2</b> Additional likelihood specification</a></li>
<li class="chapter" data-level="C.3.3" data-path="fast-approximate-bayesian-inference.html"><a href="fast-approximate-bayesian-inference.html#naomi-identifiability"><i class="fa fa-check"></i><b>C.3.3</b> Identifiability constraints</a></li>
<li class="chapter" data-level="C.3.4" data-path="fast-approximate-bayesian-inference.html"><a href="fast-approximate-bayesian-inference.html#naomi-implementation"><i class="fa fa-check"></i><b>C.3.4</b> Implementation</a></li>
</ul></li>
<li class="chapter" data-level="C.4" data-path="fast-approximate-bayesian-inference.html"><a href="fast-approximate-bayesian-inference.html#nuts-convergence-and-suitability-2"><i class="fa fa-check"></i><b>C.4</b> NUTS convergence and suitability</a></li>
<li class="chapter" data-level="C.5" data-path="fast-approximate-bayesian-inference.html"><a href="fast-approximate-bayesian-inference.html#use-of-pca-aghq-1"><i class="fa fa-check"></i><b>C.5</b> Use of PCA-AGHQ</a></li>
<li class="chapter" data-level="C.6" data-path="fast-approximate-bayesian-inference.html"><a href="fast-approximate-bayesian-inference.html#normalising-constant-estimation"><i class="fa fa-check"></i><b>C.6</b> Normalising constant estimation</a></li>
<li class="chapter" data-level="C.7" data-path="fast-approximate-bayesian-inference.html"><a href="fast-approximate-bayesian-inference.html#inference-comparison-2"><i class="fa fa-check"></i><b>C.7</b> Inference comparison</a></li>
</ul></li>
</ul>

      </nav>
    </div>

    <div class="book-body">
      <div class="body-inner">
        <div class="book-header" role="navigation">
          <h1>
            <i class="fa fa-circle-o-notch fa-spin"></i><a href="./"><p>Bayesian spatio-temporal methods for small-area estimation of HIV indicators</p></a>
          </h1>
        </div>

        <div class="page-wrapper" tabindex="-1" role="main">
          <div class="page-inner">

            <section class="normal" id="section-">
<div id="hiv-aids" class="section level1 hasAnchor" number="2">
<h1><span class="header-section-number">2</span> The HIV/AIDS epidemic<a href="hiv-aids.html#hiv-aids" class="anchor-section" aria-label="Anchor link to header"></a></h1>
<!-- For PDF output, include these two LaTeX commands after unnumbered chapter headings, otherwise the mini table of contents and the running header will show the previous chapter -->
<div id="background" class="section level2 hasAnchor" number="2.1">
<h2><span class="header-section-number">2.1</span> Background<a href="hiv-aids.html#background" class="anchor-section" aria-label="Anchor link to header"></a></h2>
<!-- What is HIV -->
<p>HIV is a retrovirus which infects humans.
If untreated, HIV can develop into a more advanced stage known as acquired immunodeficiency syndrome (AIDS).
HIV primarily attacks a type of white blood cell vital for the function of the immune system.
As a result, AIDS is characterised by increased risk of developing opportunistic infections such as tuberculosis or <em>Pneumocystis</em> pneumonias, which can result in death.</p>
<!-- HIV is a big problem, plus how is it transmitted -->
<p>The first AIDS cases were reported in Los Angeles in the early 1980s <span class="citation">(<a href="#ref-gottlieb1981pneumocystis">Gottlieb et al. 1981</a>; <a href="#ref-barre1983isolation">Barré-Sinoussi et al. 1983</a>)</span>.
Since then, HIV has spread globally.
Transmission occurs by exposure to specific bodily fluids of an infected person.
The most common mode of transmission is via unprotected anal or vaginal sex.
Transmission can also occur from a mother to her baby, or when drug injection equipment is shared.
Approximately 86 million people have become infected with HIV, and of those 40 million have died of AIDS-related causes <span class="citation">(<a href="#ref-unaids2023aidsinfo">UNAIDS 2023a</a>)</span>.</p>
<!-- A lot of effort going into it -->
<p>An ongoing global effort has been made to respond to the epidemic.
The response has been multifaceted, shaped by local communities, civil society organisations, national governments, research institutions, pharmaceutical companies, international agencies like the Joint United Nations Programme
on HIV/AIDS (UNAIDS), and global health initiatives such like the President’s Emergency Plan for AIDS Relief (PEPFAR) and the Global Fund to Fight AIDS, Tuberculosis, and Malaria (the Global Fund).
The investment of $100 billion by PEPFAR constitutes the “largest commitment by a single nation to address a single disease in history” <span class="citation">(<a href="#ref-pepfar2022">U.S. Department of State 2022</a>)</span>, indicating the scale of the response.</p>

<div class="figure" style="text-align: centre"><span style="display:block;" id="fig:overall-picture"></span>
<img src="figures/hiv-aids/overall-picture.png" alt="Globally, yearly new HIV infections peaked in 1995, and have since decreased by 59%. Yearly AIDS-related deaths peaked in 2004, and have since decreased by 68% (UNAIDS 2023a). Much of the global disease burden is concentrated in eastern and southern Africa, as well as western and central Africa. The unit “M” refers to millions. The colour palette used in this figure, and throughout the theiss, is that of Okabe and Ito (2008). It is designed to be colourblind friendly, and the default in Wilke (2019)." width="95%" />
<p class="caption">
Figure 2.1: Globally, yearly new HIV infections peaked in 1995, and have since decreased by 59%. Yearly AIDS-related deaths peaked in 2004, and have since decreased by 68% <span class="citation">(<a href="#ref-unaids2023aidsinfo">UNAIDS 2023a</a>)</span>. Much of the global disease burden is concentrated in eastern and southern Africa, as well as western and central Africa. The unit “M” refers to millions. The colour palette used in this figure, and throughout the theiss, is that of <span class="citation">Okabe and Ito (<a href="#ref-okabe2008color">2008</a>)</span>. It is designed to be colourblind friendly, and the default in <span class="citation">Wilke (<a href="#ref-wilke2019fundamentals">2019</a>)</span>.
</p>
</div>
<!-- The effort has translated into progress -->
<p>Implementation of HIV prevention and treatment has significantly reduced the number of new HIV infections and AIDS-related deaths per year since their respective peaks (Figure <a href="hiv-aids.html#fig:overall-picture">2.1</a>).
The most significant evidence-based interventions, in approximately chronological order of their introduction, are described below:</p>
<ul>
<li><p>Condoms are an inexpensive and effective method for prevention of HIV and other sexually transmitted infections (STIs) such as <em>Chlamydia trachomatis</em>, <em>Neisseria gonorrhoeae</em>, syphilis, and <em>Trichomonas vaginalis</em>.
Condom usage has increased significantly since 1990, which is estimated to have averted 117 million new HIV infections <span class="citation">(<a href="#ref-stover2021impact">Stover and Teng 2021</a>)</span>.
There remain significant but difficult to close gaps in condom usage.</p></li>
<li><p>Antiretroviral therapy (ART) is a combination of drugs which stop the virus from replicating in the body.
A person living with HIV who takes ART daily can live a full and healthy life, transforming what was once a terminal illness to a treatable chronic condition.
Of the 39 million people living with HIV (PLHIV) in 2022, around 76% were accessing ART.
The number of AIDS-related deaths, 21 million, estimated to have been averted by ART is staggering <span class="citation">(<a href="#ref-unaids2023global">UNAIDS 2023b</a>)</span>.</p>
<p>ART reduces the amount of virus in the blood and genital secretions.
If the virus is undetectable then there is significant evidence that it cannot be transmitted sexually <span class="citation">(<a href="#ref-cohen2011prevention">Cohen et al. 2011</a>; <a href="#ref-broyles2023risk">Broyles et al. 2023</a>)</span>.
For this reason, in addition to providing life saving treatment, ART also operates as prevention.
Approaches to lowering risk of HIV transmission this way are referred to as treatment as prevention (TaSP).
Particular efforts have been made to provide pregnant women with ART to reduce the chance of mother-to-child transmission (MTCT) <span class="citation">(<a href="#ref-siegfried2011antiretrovirals">Siegfried et al. 2011</a>)</span>.</p></li>
<li><p>Voluntary medical male circumcision (VMMC) partially protects against female-to-male HIV acquisition.
Three landmark randomised control trials (RCTs) <span class="citation">(<a href="#ref-auvert2005randomized">Auvert et al. 2005</a>; <a href="#ref-gray2007male">Gray et al. 2007</a>; <a href="#ref-bailey2007male">Bailey et al. 2007</a>)</span> found complete surgical removal of the foreskin to result a reduction of HIV acquisition in men by 50-60%.
Based on this evidence, VMMC has been recommended since 2007 by the World Health Organization (WHO) and UNAIDS as a key HIV intervention in high-prevalence settings <span class="citation">(<a href="#ref-world2007new">WHO and UNAIDS 2007</a>)</span>.
Scale up of VMMC across 15 priority countries between 2008 and 2019 is estimated to have already averted 340 thousand new HIV infections, though the future number of new HIV infections averted is likely to be much higher <span class="citation">(<a href="#ref-mcgillen2018emerging">McGillen et al. 2018</a>; <a href="#ref-unaids2021vmmc">UNAIDS and WHO 2021</a>)</span>.</p></li>
<li><p>Pre-exposure prophylaxis (PrEP) and post-exposure prophylaxis (PEP) are antiretroviral drugs which can be taken before and after exposure to prevent transmission.
PrEP has been shown to be effective at an individual-level across a number of RCTs <span class="citation">(<a href="#ref-baeten2012antiretroviral">Baeten et al. 2012</a>; <a href="#ref-thigpen2012antiretroviral">Thigpen et al. 2012</a>)</span>, but there are few population-level studies.
Though PEP cannot be studied with RCTs, observational studies indicate it is highly effective <span class="citation">(<a href="#ref-dominguez2016updated">Dominguez et al. 2016</a>)</span>.
These medical interventions are more costly than some other options, so are primarily useful in high risk settings.</p></li>
</ul>
<p>Though important progress had been made, facilitated by the interventions above, there remains much more to do.
In 2022, 1.3 million people were newly infected with HIV and there were 630 thousand AIDS-related deaths, more than one every minute <span class="citation">(<a href="#ref-unaids2022global">UNAIDS 2022</a>)</span>.
Bold fast-track targets have been set to accelerate the end of AIDS as global public health threat by 2030.
To meet these targets in the context of disruption to HIV services caused by the COVID-19 pandemic and a potential shortfall in HIV funding, renewed commitments are required <span class="citation">(<a href="#ref-economist2023triple">Economist Impact 2023</a>)</span>.</p>

<div class="figure" style="text-align: centre"><span style="display:block;" id="fig:naomi-continent"></span>
<img src="figures/hiv-aids/naomi-continent.png" alt="Adult (15-49) HIV prevalence varies substantially both within and between countries in SSA. The estimates from 2023 were generated by country teams using the Naomi small-area estimation model in a process supported by UNAIDS, and are available from UNAIDS (2023a). White filled points are country-level estimates, and coloured points are district-level estimates. Results from Nigeria were not published. Data collection in the Cabo Delgado province of Mozambique was disrupted by conflict. Obtaining results for the Democratic Republic of the Congo required removing some districts from the model." width="95%" />
<p class="caption">
Figure 2.2: Adult (15-49) HIV prevalence varies substantially both within and between countries in SSA. The estimates from 2023 were generated by country teams using the Naomi small-area estimation model in a process supported by UNAIDS, and are available from <span class="citation">UNAIDS (<a href="#ref-unaids2023aidsinfo">2023a</a>)</span>. White filled points are country-level estimates, and coloured points are district-level estimates. Results from Nigeria were not published. Data collection in the Cabo Delgado province of Mozambique was disrupted by conflict. Obtaining results for the Democratic Republic of the Congo required removing some districts from the model.
</p>
</div>
<!-- Prioritisation of interventions  -->
<p>For available resources to have the greatest impact, it is important that the right HIV interventions to be prioritised to the right populations, in the right place, and at the right time.
By analogy to precision medicine, this paradigm has been termed precision public health <span class="citation">(<a href="#ref-khoury2016precision">Khoury, Iademarco, and Riley 2016</a>)</span>.
While precision medicine tailors treatments to the individual, precision public health tailors treatments to the population.
Differences in the cost-effectiveness of any given intervention can be vast, with some interventions orders of magnitude more impactful than others <span class="citation">(<a href="#ref-ord2013moral">Ord 2013</a>)</span>.</p>
<!-- Uneven burden in space -->
<p>Disease burden varies substantially across multiple spatial scales.
In some countries, the epidemic is concentrated in small populations, and national HIV prevalence is low.
In others, the epidemic is sustained by heterosexual transmission, and national HIV prevalence is higher (typically &gt;1%)
These two epidemic settings are sometimes described as concentrated and generalised, respectively.
Most of the countries severely affected by HIV are in sub-Saharan Africa (SSA).
It is estimated that 66% of the 39 million PLHIV worldwide live in SSA.
Adult HIV prevalence (ages 15-49) is above 10% in some countries in southern Africa, with some districts even exceeding 20% (Figure <a href="hiv-aids.html#fig:naomi-continent">2.2</a>).
Indeed, just as there is variation between countries, there is variation within countries.
As an illustration, adult HIV prevalence at the district municipality level in South Africa ranges from 6% in Namakwa to 30% in uMkhanyakude.
Accordingly, the work in this thesis is centred on measurement of HIV at the district level in SSA.</p>
<!-- Uneven burden across people -->
<p>In all countries and contexts, some groups of people are at much higher risk than others.
Groups of people at increased risk of HIV infection are known as key populations (KPs).
Examples include men who have sex with men (MSM), female sex workers (FSW), people who inject drugs (PWID), and transgender people (TGP) <span class="citation">(<a href="#ref-stevens2023estimating">Stevens et al. 2023</a>)</span>.
KPs are often marginalised, and face legal and social barriers.
Concentrated settings are defined by the majority of new HIV infections occurring in KPs and their sexual partners.
In generalised settings like SSA, though concentrated subepidemics do occur <span class="citation">(<a href="#ref-tanser2014concentrated">Tanser et al. 2014</a>)</span>, risk is more diffuse across the population.
In SSA adolescent girls and young women (AGYW) are a large demographic group at increased risk of HIV infection <span class="citation">(<a href="#ref-risher2021age">Risher et al. 2021</a>; <a href="#ref-monod2023longitudinal">Monod et al. 2023</a>)</span> but not typically considered a KP.
Chapter <a href="multi-agyw.html#multi-agyw">5</a> focuses on measurement of HIV for AGYW and FSW.</p>
<!-- Practical methods for prevention prioritisation: what is being done and is it working -->
<p>There are a number of ways to practically implement differentiated HIV treatment and prevention services <span class="citation">(<a href="#ref-godfrey2022hiv">Godfrey-Faussett et al. 2022</a>)</span>.
These include geographic and demographic prioritisation <span class="citation">(<a href="#ref-meyer2018targeting">Meyer-Rath et al. 2018</a>)</span>, key population services <span class="citation">(<a href="#ref-world2022consolidated">Organization et al. 2022</a>)</span>, and risk screening based on individual-level risk characteristics <span class="citation">(<a href="#ref-jia2022risk">Jia et al. 2022</a>)</span>.
Each approach requires strategic information about HIV disease burden.
This thesis focuses on using HIV surveillance to inform geographic and demographic prioritisation.</p>
</div>
<div id="surveillance" class="section level2 hasAnchor" number="2.2">
<h2><span class="header-section-number">2.2</span> HIV surveillance<a href="hiv-aids.html#surveillance" class="anchor-section" aria-label="Anchor link to header"></a></h2>
<!-- What is surveillance and how can it be used to meet these needs -->
<p>HIV surveillance refers to the collection, analysis, interpretation and dissemination of data relating to HIV <span class="citation">(<a href="#ref-pisani2003hiv">Pisani et al. 2003</a>)</span>.
Surveillance can be used to track epidemic indicators, identify at-risk populations, uncover drivers of transmission, implement prevention and treatment programs, and assess their impact.
Important indicators to measure include:</p>
<ul>
<li><p><strong>HIV prevalence</strong> is the proportion <span class="math inline">\(\rho \in [0, 1]\)</span> of a population who have HIV.
The number of PLHIV is given by <span class="math inline">\(N\rho\)</span>, where <span class="math inline">\(N\)</span> is the (living) population size.
Increases in HIV prevalence, and the number of PLHIV, can be caused either by new HIV infections or more PLHIV remaining alive by taking treatment.
For this reason it is important to take caution in directly interpreting changes in HIV prevalence.
Nonetheless, as a primary measure of population disease burden, HIV prevalence is crucial in calculating all of the other indicators given below.</p></li>
<li><p><strong>HIV incidence</strong> is the rate <span class="math inline">\(\lambda &gt; 0\)</span> of new HIV infections.
In writing, HIV incidence is often given as a number of new infections per 1000 person years.
The number of new HIV infections that occur during a given time is the integral of the rate of HIV incidence multiplied by the size of the susceptible population.
Let <span class="math inline">\(\rho_t\)</span> be the HIV prevalence, and <span class="math inline">\(N_t\)</span> be the population size, at time <span class="math inline">\(t\)</span>.
Then the number of new HIV infections which occur during a given period of time are given by
<span class="math display">\[
I = \int \lambda_t \cdot (1 - \rho_t) \cdot N_t \text{d}t.
\]</span>
Planning, delivery, and evaluation of prevention programming relies on estimates of HIV incidence and the number of new HIV infections.
Knowing whether the rate of new infections is rising or declining within specific populations is crucial.</p></li>
<li><p><strong>ART coverage</strong> is the proportion <span class="math inline">\(\alpha \in [0, 1]\)</span> of PLHIV who are on ART.
The number of people taking ART is given by <span class="math inline">\(N \cdot \rho \cdot \alpha\)</span>.
Estimates of ART coverage play a direct role in planning provision of treatment services, and finding unmet treatment need.</p></li>
<li><p><strong>Recent infection</strong> is the proportion <span class="math inline">\(\kappa \in [0, 1]\)</span> of PLHIV who have been recently infected.
Recency assays use biomarkers to distinguish between recent and longstanding infection, with varying sensitivity and specificity.
Estimates of recent infection are primarily used to help estimate HIV incidence <span class="citation">(<a href="#ref-kassanjee2012new">Kassanjee et al. 2012</a>; <a href="#ref-unaids2022using">UNAIDS, WHO, et al. 2022</a>)</span>.</p></li>
<li><p><strong>Awareness of status</strong> is the proportion <span class="math inline">\(\xi \in [0, 1]\)</span> of PLHIV who have been diagnosed with HIV.
Programming of HIV testing and diagnosis is informed by estimates of awareness of HIV status.
HIV diagnosis allows for linkage to care and progression along the HIV treatment cascade and care continuum <span class="citation">(<a href="#ref-cdc2014">CDC 2014</a>)</span>.</p></li>
</ul>
<div id="hiv-data" class="section level3 hasAnchor" number="2.2.1">
<h3><span class="header-section-number">2.2.1</span> Data<a href="hiv-aids.html#hiv-data" class="anchor-section" aria-label="Anchor link to header"></a></h3>
<p>Measuring the above HIV indicators requires data.
To give the most complete picture of the epidemic, it is important to use multiple sources of data.
The most prominent categories are:</p>
<ul>
<li><p><strong>Household surveys</strong> are large, national, cross-sectional studies.
The surveys conducted in the most countires are Demographic and Health Surveys [DHS ;<span class="citation">USAID (<a href="#ref-measure2012sampling">2012</a>)</span>], which include a wide range of health related questions, and more HIV-specific Population-based HIV Impact Assessment [PHIA; <span class="citation">ICAP (<a href="#ref-phia">2023</a>)</span>] and AIDS Indicator Surveys (AIS).
Some countries also implement their own survey series, such as the South Africa Behavioural, Sero-status and Media Impact Survey (SABSSM).
Household surveys provide high quality standardised data about HIV, typically designed to furnish nationally-representative estimates.
Both DHS and PHIA surveys collecting demographic, behavioural, and clinical information.
Additionally, HIV testing is conducted via home-based testing, with results returned immediately, or anonymous dried blood spot testing.</p></li>
<li><p><strong>Programmatic data</strong> refer to data routinely collected during delivery of health services.
Examples include data from antenatal care (ANC) HIV testing and ART service delivery.
Due to their integration with regular service delivery, programmatic data are available at higher frequency than other data sources.
However, in comparison with designed studies, less control can be exercised over collection of programmatic data.
It is common to encounter issues of data quality and reliability, as well as bias, in working with programmatic data.</p></li>
<li><p><strong>Cohort studies</strong> follow a group of people over time.
Outcomes may be measured more systematically in a cohort study than in other study designs.
The data from cohort studies have particular use in informing otherwise difficult to estimate epidemiological parameters.
Such parameters include disease progression and mortality rates, transmission dynamics, and treatment outcomes.
Examples of population-based cohort studies in SSA include the Manicaland Project Open Cohort Study in Zimbabwe <span class="citation">(<a href="#ref-gregson2006hiv">Gregson et al. 2006</a>)</span>, the Rakai Community Cohort Study in Uganda <span class="citation">(<a href="#ref-grabowski2017hiv">Grabowski et al. 2017</a>)</span>, and the Karonga Demographic Surveillance Site in Malawi <span class="citation">(<a href="#ref-crampin2012profile">Crampin et al. 2012</a>)</span>.</p></li>
</ul>
</div>
<div id="challenges" class="section level3 hasAnchor" number="2.2.2">
<h3><span class="header-section-number">2.2.2</span> Challenges<a href="hiv-aids.html#challenges" class="anchor-section" aria-label="Anchor link to header"></a></h3>
<p>Obtaining reliable, timely estimates of the HIV indicators at an appropriate spatial resolution using the available data sources is challenging.
The most significant difficulties faced are enumerated below, providing important context for the work in this thesis:</p>
<ol style="list-style-type: decimal">
<li><p><strong>Data sparsity</strong>:
Collection of data is costly and time consuming.
As a result, limited direct data might be available for the particular time, location, or population of interest.
For example, in many countries the last conducted household survey is several years out of date.
Furthermore, the sample sizes in household surveys are typically designed to be representative at a national-level.
As a result, data for subpopulations are usually sparse.</p></li>
<li><p><strong>Missing data</strong>:
The sampling frame of a survey may not correspond to the target population.
For example, some KPs are difficult to reach, and may be omitted from sampling frames <span class="citation">(<a href="#ref-jin2021overview">Jin, Restar, and Beyrer 2021</a>)</span>.
Additionally, individuals included on the sampling frame may choose not to respond.
Each of these issues can be characterised as being problems of missing data.</p></li>
<li><p><strong>Response and measurement biases</strong>:
Individuals may be hesitant to disclose their HIV status, or report higher risk behaviours, due to social desirability bias or a fear of discrimination or stigma.
When available, biomarker data can be used to overcome under-reporting of HIV status, but still may be subject to measurement errors.
Biases in behavioural data can be more difficult to disentangle.</p></li>
<li><p><strong>Denominators and demography</strong>:
Many indicators are rates or proportions, which rely on estimates of the population at risk in the denominator.
For example, HIV prevalence is a proportion of the population, and HIV incidence is a rate per person-years at risk.
Accurately estimating population denominators over space, time, and demographies is itself a challenging task <span class="citation">(<a href="#ref-tatem2017worldpop">Tatem 2017</a>)</span>.
Taking a ratio of uncertain quantities amplifies uncertainty, but is rarely properly accounted for.</p></li>
<li><p><strong>Inconsistent data collection and reporting</strong>:
The sources of data that are collected might vary across space and time.
Additionally, reporting protocols or definitions for the same data source can also change.
Though household surveys tend to be more consistent than programmatic data, the questions included and design of the surveys do change.</p></li>
<li><p><strong>Reliance on epidemiological parameters</strong>:
Indicators rely on estimates of epidemiological parameters such as rates of disease progression.
These parameters may not generalise to the setting of interest.
Further, they are typically applied coarsely, and without proper accounting for uncertainty.</p></li>
</ol>
</div>
<div id="statistical-approaches" class="section level3 hasAnchor" number="2.2.3">
<h3><span class="header-section-number">2.2.3</span> Statistical approaches<a href="hiv-aids.html#statistical-approaches" class="anchor-section" aria-label="Anchor link to header"></a></h3>
<p>The challenges above make direct interpretation of the data often misleading or impossible.
Careful statistical modelling is required to mitigate these limitations as effectively as possible.
The most important statistical approaches for estimating HIV indicators used in this thesis are:</p>
<ol style="list-style-type: decimal">
<li><p><strong>Borrowing information</strong>:
When little direct data are available, data judged to be indirectly related can be used to help improve estimation.
For example, if limited data are available for individuals of a certain age, it is likely reasonable to make use of data for individuals of a similar age.
As well as over age groups, information can be borrowed between and within countries, and across times.
Chapter <a href="beyond-borders.html#beyond-borders">4</a> discusses models for borrowing information over space.
These models, along with others for borrowing information in other dimensions, are applied in Chapters <a href="multi-agyw.html#multi-agyw">5</a> and <a href="naomi-aghq.html#naomi-aghq">6</a>.</p></li>
<li><p><strong>Evidence synthesis</strong>:
Multiple sources of evidence can be combined to overcome the limitations of any one data source.
For example, infrequently run household surveys can be complemented by more up-to-date programmatic data.
Chapter <a href="naomi-aghq.html#naomi-aghq">6</a> develops methods suitable for the complex statistical models required to integrate data sources.
Multiple data sources are used in Chapter <a href="multi-agyw.html#multi-agyw">5</a> to overcome the limitations of household surveys for measuring KP population sizes.</p></li>
<li><p><strong>Expert guidance</strong>:
Expert epidemiological, demographic, and local stakeholder guidance can be used to improve estimates.
Ensuring the quality of any data used in the estimation process is essential.</p></li>
<li><p><strong>Uncertainty quantification</strong>:
Conclusions drawn by synthesising multiple incomplete data sources are unlikely to be firm and unanimous.
It is therefore especially important that the uncertainties inherent to any statistical analysis are accurately and transparently presented.
The Bayesian statistical paradigm introduced in Chapter <a href="bayes-st.html#bayes-st">3</a> and used throughout this thesis is particularly well suited to handling of uncertainty.</p></li>
</ol>

</div>
</div>
</div>
<h3>References</h3>
<div id="refs" class="references csl-bib-body hanging-indent">
<div id="ref-auvert2005randomized" class="csl-entry">
Auvert, Bertran, Dirk Taljaard, Emmanuel Lagarde, Joelle Sobngwi-Tambekou, Rémi Sitta, and Adrian Puren. 2005. <span>“<span class="nocase">Randomized, controlled intervention trial of male circumcision for reduction of HIV infection risk: the ANRS 1265 Trial</span>.”</span> <em>PLoS Medicine</em> 2 (11): e298.
</div>
<div id="ref-baeten2012antiretroviral" class="csl-entry">
Baeten, Jared M, Deborah Donnell, Patrick Ndase, Nelly R Mugo, James D Campbell, Jonathan Wangisi, Jordan W Tappero, et al. 2012. <span>“Antiretroviral Prophylaxis for HIV Prevention in Heterosexual Men and Women.”</span> <em>New England Journal of Medicine</em> 367 (5): 399–410.
</div>
<div id="ref-bailey2007male" class="csl-entry">
Bailey, Robert C, Stephen Moses, Corette B Parker, Kawango Agot, Ian Maclean, John N Krieger, Carolyn FM Williams, Richard T Campbell, and Jeckoniah O Ndinya-Achola. 2007. <span>“<span class="nocase">Male circumcision for HIV prevention in young men in Kisumu, Kenya: a randomised controlled trial</span>.”</span> <em>The Lancet</em> 369 (9562): 643–56.
</div>
<div id="ref-barre1983isolation" class="csl-entry">
Barré-Sinoussi, Françoise, Jean-Claude Chermann, Fran Rey, Marie Therese Nugeyre, Sophie Chamaret, Jacqueline Gruest, Charles Dauguet, et al. 1983. <span>“<span class="nocase">Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS)</span>.”</span> <em>Science</em> 220 (4599): 868–71.
</div>
<div id="ref-broyles2023risk" class="csl-entry">
Broyles, Laura N, Robert Luo, Debi Boeras, and Lara Vojnov. 2023. <span>“<span class="nocase">The risk of sexual transmission of HIV in individuals with low-level HIV viraemia: a systematic review</span>.”</span> <em>The Lancet</em>.
</div>
<div id="ref-cdc2014" class="csl-entry">
CDC. 2014. <span>“Understanding the <span>HIV</span> Care Continuum.”</span> CDC. <a href="http://www.cdc.gov/hiv/pdf/dhap_continuum.pdf">http://www.cdc.gov/hiv/pdf/dhap_continuum.pdf</a>.
</div>
<div id="ref-cohen2011prevention" class="csl-entry">
Cohen, Myron S, Ying Q Chen, Marybeth McCauley, Theresa Gamble, Mina C Hosseinipour, Nagalingeswaran Kumarasamy, James G Hakim, et al. 2011. <span>“<span class="nocase">Prevention of HIV-1 infection with early antiretroviral therapy</span>.”</span> <em>New England Journal of Medicine</em> 365 (6): 493–505.
</div>
<div id="ref-crampin2012profile" class="csl-entry">
Crampin, Amelia C, Albert Dube, Sebastian Mboma, Alison Price, Menard Chihana, Andreas Jahn, Angela Baschieri, et al. 2012. <span>“<span class="nocase">Profile: the Karonga health and demographic surveillance system</span>.”</span> <em><span>International Journal of Epidemiology</span></em> 41 (3): 676–85.
</div>
<div id="ref-dominguez2016updated" class="csl-entry">
Dominguez, Kenneth L., Dawn K. Smith, Vasavi Thomas, Nicole Crepaz, Karen Lang, Walid Heneine, Janet M. McNicholl, et al. 2016. <span>“Updated Guidelines for Antiretroviral Postexposure Prophylaxis After Sexual, Injection Drug Use, or Other Nonoccupational Exposure to HIV—United States, 2016.”</span> <a href="https://stacks.cdc.gov/view/cdc/38856">https://stacks.cdc.gov/view/cdc/38856</a>.
</div>
<div id="ref-economist2023triple" class="csl-entry">
Economist Impact. 2023. <span>“<span class="nocase">A triple dividend: the health, social and economic gains from financing the HIV response in Africa</span>.”</span>
</div>
<div id="ref-godfrey2022hiv" class="csl-entry">
Godfrey-Faussett, Peter, Luisa Frescura, Quarraisha Abdool Karim, Michaela Clayton, Peter D Ghys, and 2025 prevention targets working group). 2022. <span>“HIV Prevention for the Next Decade: Appropriate, Person-Centred, Prioritised, Effective, Combination Prevention.”</span> <em>PLoS Medicine</em> 19 (9): e1004102.
</div>
<div id="ref-gottlieb1981pneumocystis" class="csl-entry">
Gottlieb, Michael S, Howard M Schanker, Peng Thim Fan, Andrew Saxon, Joel D Weisman, Irving Pozalski, et al. 1981. <span>“<span class="nocase">Pneumocystis pneumonia—Los Angeles</span>.”</span> <em>Morbidity and Mortality Weekly Report</em> 30 (21): 1–3.
</div>
<div id="ref-grabowski2017hiv" class="csl-entry">
Grabowski, M Kate, David M Serwadda, Ronald H Gray, Gertrude Nakigozi, Godfrey Kigozi, Joseph Kagaayi, Robert Ssekubugu, et al. 2017. <span>“<span class="nocase">HIV prevention efforts and incidence of HIV in Uganda</span>.”</span> <em>New England Journal of Medicine</em> 377 (22): 2154–66.
</div>
<div id="ref-gray2007male" class="csl-entry">
Gray, Ronald H, Godfrey Kigozi, David Serwadda, Frederick Makumbi, Stephen Watya, Fred Nalugoda, Noah Kiwanuka, et al. 2007. <span>“<span class="nocase">Male circumcision for HIV prevention in men in Rakai, Uganda: a randomised trial</span>.”</span> <em>The Lancet</em> 369 (9562): 657–66.
</div>
<div id="ref-gregson2006hiv" class="csl-entry">
Gregson, Simon, Geoffrey P Garnett, Constance A Nyamukapa, Timothy B Hallett, James JC Lewis, Peter R Mason, Stephen K Chandiwana, and Roy M Anderson. 2006. <span>“<span class="nocase">HIV decline associated with behavior change in eastern Zimbabwe</span>.”</span> <em>Science</em> 311 (5761): 664–66.
</div>
<div id="ref-phia" class="csl-entry">
ICAP. 2023. <span>“<span class="nocase">Population-based HIV impact assessment: guiding the global HIV response</span>.”</span> <a href="https://phia.icap.columbia.edu">https://phia.icap.columbia.edu</a>.
</div>
<div id="ref-jia2022risk" class="csl-entry">
Jia, Katherine M, Hallie Eilerts, Olanrewaju Edun, Kevin Lam, Adam Howes, Matthew L Thomas, and Jeffrey W Eaton. 2022. <span>“<span class="nocase">Risk scores for predicting HIV incidence among adult heterosexual populations in sub-Saharan Africa: a systematic review and meta-analysis</span>.”</span> <em>Journal of the International AIDS Society</em> 25 (1): e25861.
</div>
<div id="ref-jin2021overview" class="csl-entry">
Jin, Harry, Arjee Restar, and Chris Beyrer. 2021. <span>“Overview of the Epidemiological Conditions of HIV Among Key Populations in Africa.”</span> <em>Journal of the International AIDS Society</em> 24: e25716.
</div>
<div id="ref-kassanjee2012new" class="csl-entry">
Kassanjee, Reshma, Thomas A. McWalter, Till Bärnighausen, and Alex Welte. 2012. <span>“A New General Biomarker-Based Incidence Estimator.”</span> <em>Epidemiology</em> 23 (5).
</div>
<div id="ref-khoury2016precision" class="csl-entry">
Khoury, Muin J, Michael F Iademarco, and William T Riley. 2016. <span>“<span class="nocase">Precision public health for the era of precision medicine</span>.”</span> <em>American Journal of Preventive Medicine</em> 50 (3): 398–401.
</div>
<div id="ref-mcgillen2018emerging" class="csl-entry">
McGillen, Jessica B, John Stover, Daniel J Klein, Sinokuthemba Xaba, Getrude Ncube, Mutsa Mhangara, Geraldine N Chipendo, et al. 2018. <span>“The Emerging Health Impact of Voluntary Medical Male Circumcision in Zimbabwe: An Evaluation Using Three Epidemiological Models.”</span> <em>PloS One</em> 13 (7): e0199453.
</div>
<div id="ref-meyer2018targeting" class="csl-entry">
Meyer-Rath, Gesine, Jessica B McGillen, Diego F Cuadros, Timothy B Hallett, Samir Bhatt, Njeri Wabiri, Frank Tanser, and Thomas Rehle. 2018. <span>“Targeting the Right Interventions to the Right People and Places: The Role of Geospatial Analysis in HIV Program Planning.”</span> <em>AIDS (London, England)</em> 32 (8): 957.
</div>
<div id="ref-monod2023longitudinal" class="csl-entry">
Monod, Mélodie, Andrea Brizzi, Ronald M. Galiwango, Robert Ssekubugu, Yu Chen, Xiaoyue Xi, Edward Nelson Kankaka, et al. 2023. <span>“Longitudinal Population-Level HIV Epidemiologic and Genomic Surveillance Highlights Growing Gender Disparity of HIV Transmission in Uganda.”</span> <em>Nature Microbiology</em>.
</div>
<div id="ref-okabe2008color" class="csl-entry">
Okabe, Masataka, and Kei Ito. 2008. <span>“Color Universal Design (CUD): How to Make Figures and Presentations That Are Friendly to Colorblind People.”</span> 2008. <a href="http://jfly.iam.u-tokyo.ac.jp/color/">http://jfly.iam.u-tokyo.ac.jp/color/</a>.
</div>
<div id="ref-ord2013moral" class="csl-entry">
Ord, Toby. 2013. <span>“<span class="nocase">The moral imperative toward cost-effectiveness in global health</span>.”</span> <em>Center for Global Development</em> 12.
</div>
<div id="ref-world2022consolidated" class="csl-entry">
Organization, World Health et al. 2022. <em>Consolidated Guidelines on HIV, Viral Hepatitis and STI Prevention, Diagnosis, Treatment and Care for Key Populations</em>. World Health Organization.
</div>
<div id="ref-pisani2003hiv" class="csl-entry">
Pisani, Elizabeth, Stefano Lazzari, Neff Walker, and Bernhard Schwartländer. 2003. <span>“<span class="nocase">HIV surveillance: a global perspective</span>.”</span> <em>JAIDS Journal of Acquired Immune Deficiency Syndromes</em> 32: S3–11.
</div>
<div id="ref-risher2021age" class="csl-entry">
Risher, Kathryn A, Anne Cori, Georges Reniers, Milly Marston, Clara Calvert, Amelia Crampin, Tawanda Dadirai, et al. 2021. <span>“<span class="nocase">Age patterns of HIV incidence in eastern and southern Africa: a modelling analysis of observational population-based cohort studies</span>.”</span> <em>The Lancet HIV</em> 8 (7): e429–39.
</div>
<div id="ref-siegfried2011antiretrovirals" class="csl-entry">
Siegfried, Nandi, Lize van der Merwe, Peter Brocklehurst, and Tin Tin Sint. 2011. <span>“<span class="nocase">Antiretrovirals for reducing the risk of mother-to-child transmission of HIV infection</span>.”</span> <em>Cochrane Database of Systematic Reviews</em>, no. 7.
</div>
<div id="ref-stevens2023estimating" class="csl-entry">
Stevens, Oliver, Keith Sabin, Rebecca Anderson, Sonia Arias Garcia, Kalai Willis, Amrita Rao, Anne F. McIntyre, et al. 2023. <span>“<span class="nocase">Population size, HIV prevalence, and antiretroviral therapy coverage among key populations in sub-Saharan Africa: collation and synthesis of survey data 2010-2023</span>.”</span> <em>medRxiv</em>. <a href="https://www.medrxiv.org/content/early/2023/11/22/2022.07.27.22278071">https://www.medrxiv.org/content/early/2023/11/22/2022.07.27.22278071</a>.
</div>
<div id="ref-stover2021impact" class="csl-entry">
Stover, John, and Yu Teng. 2021. <span>“<span class="nocase">The impact of condom use on the HIV epidemic</span>.”</span> <em>Gates Open Research</em> 5.
</div>
<div id="ref-tanser2014concentrated" class="csl-entry">
Tanser, Frank, Tulio de Oliveira, Mathieu Maheu-Giroux, and Till Bärnighausen. 2014. <span>“<span class="nocase">Concentrated HIV sub-epidemics in generalized epidemic settings</span>.”</span> <em>Current Opinion in HIV and AIDS</em> 9 (2): 115.
</div>
<div id="ref-tatem2017worldpop" class="csl-entry">
Tatem, Andrew J. 2017. <span>“<span class="nocase">WorldPop, open data for spatial demography</span>.”</span> <em>Scientific Data</em> 4 (1): 1–4.
</div>
<div id="ref-thigpen2012antiretroviral" class="csl-entry">
Thigpen, Michael C, Poloko M Kebaabetswe, Lynn A Paxton, Dawn K Smith, Charles E Rose, Tebogo M Segolodi, Faith L Henderson, et al. 2012. <span>“Antiretroviral Preexposure Prophylaxis for Heterosexual HIV Transmission in Botswana.”</span> <em>New England Journal of Medicine</em> 367 (5): 423–34.
</div>
<div id="ref-unaids2022global" class="csl-entry">
UNAIDS. 2022. <span>“<span>In Danger: UNAIDS Global AIDS Update 2022</span>.”</span> <a href="https://www.unaids.org/en/resources/documents/2022/in-danger-global-aids-update" class="uri">https://www.unaids.org/en/resources/documents/2022/in-danger-global-aids-update</a>.
</div>
<div id="ref-unaids2023aidsinfo" class="csl-entry">
———. 2023a. <span>“<span class="nocase">AIDSinfo: Global data on HIV epidemiology and response</span>.”</span> <a href="https://aidsinfo.unaids.org/" class="uri">https://aidsinfo.unaids.org/</a>.
</div>
<div id="ref-unaids2023global" class="csl-entry">
———. 2023b. <span>“<span class="nocase">The path that ends AIDS: UNAIDS Global AIDS Update 2023</span>.”</span> <a href="https://www.unaids.org/en/resources/documents/2023/global-aids-update-2023" class="uri">https://www.unaids.org/en/resources/documents/2023/global-aids-update-2023</a>.
</div>
<div id="ref-unaids2021vmmc" class="csl-entry">
UNAIDS and WHO. 2021. <span>“Voluntary Medical Male Circumcision Progress Brief.”</span> UNAIDS. <a href="https://hivpreventioncoalition.unaids.org/wp-content/uploads/2021/04/JC3022_VMMC_4-pager_En_v3.pdf">https://hivpreventioncoalition.unaids.org/wp-content/uploads/2021/04/JC3022_VMMC_4-pager_En_v3.pdf</a>.
</div>
<div id="ref-unaids2022using" class="csl-entry">
UNAIDS, WHO, et al. 2022. <em>Using Recency Assays for HIV Surveillance: 2022 Technical Guidance</em>. World Health Organization.
</div>
<div id="ref-pepfar2022" class="csl-entry">
U.S. Department of State. 2022. <span>“<span>Latest Global Program Results</span>.”</span> <a href="https://www.state.gov/wp-content/uploads/2022/11/PEPFAR-Latest-Global-Results_December-2022.pdf" class="uri">https://www.state.gov/wp-content/uploads/2022/11/PEPFAR-Latest-Global-Results_December-2022.pdf</a>.
</div>
<div id="ref-measure2012sampling" class="csl-entry">
USAID. 2012. <span>“<span class="nocase">Sampling and Household Listing Manual: Demographic and Health Surveys Methodology</span>.”</span> <a href="https://dhsprogram.com/pubs/pdf/DHSM4/DHS6_Sampling_Manual_Sept2012_DHSM4.pdf">https://dhsprogram.com/pubs/pdf/DHSM4/DHS6_Sampling_Manual_Sept2012_DHSM4.pdf</a>.
</div>
<div id="ref-world2007new" class="csl-entry">
WHO and UNAIDS. 2007. <span>“New Data on Male Circumcision and HIV Prevention: Policy and Programme Implications.”</span> <em>Geneva: World Health Organization</em>.
</div>
<div id="ref-wilke2019fundamentals" class="csl-entry">
Wilke, Claus O. 2019. <em>Fundamentals of Data Visualization: A Primer on Making Informative and Compelling Figures</em>. O’Reilly Media.
</div>
</div>
            </section>

          </div>
        </div>
      </div>
<a href="introduction.html" class="navigation navigation-prev " aria-label="Previous page"><i class="fa fa-angle-left"></i></a>
<a href="bayes-st.html" class="navigation navigation-next " aria-label="Next page"><i class="fa fa-angle-right"></i></a>
    </div>
  </div>
<script src="libs/gitbook-2.6.7/js/app.min.js"></script>
<script src="libs/gitbook-2.6.7/js/clipboard.min.js"></script>
<script src="libs/gitbook-2.6.7/js/plugin-search.js"></script>
<script src="libs/gitbook-2.6.7/js/plugin-sharing.js"></script>
<script src="libs/gitbook-2.6.7/js/plugin-fontsettings.js"></script>
<script src="libs/gitbook-2.6.7/js/plugin-bookdown.js"></script>
<script src="libs/gitbook-2.6.7/js/jquery.highlight.js"></script>
<script src="libs/gitbook-2.6.7/js/plugin-clipboard.js"></script>
<script>
gitbook.require(["gitbook"], function(gitbook) {
gitbook.start({
"sharing": {
"github": false,
"facebook": false,
"twitter": true,
"linkedin": false,
"weibo": false,
"instapaper": false,
"vk": false,
"whatsapp": false,
"all": false
},
"fontsettings": {
"theme": "white",
"family": "sans",
"size": 2
},
"edit": {
"link": null,
"text": null
},
"history": {
"link": null,
"text": null
},
"view": {
"link": null,
"text": null
},
"download": null,
"search": {
"engine": "fuse",
"options": null
},
"toc": {
"collapse": "subsection"
}
});
});
</script>

<!-- dynamically load mathjax for compatibility with self-contained -->
<script>
  (function () {
    var script = document.createElement("script");
    script.type = "text/javascript";
    var src = "true";
    if (src === "" || src === "true") src = "https://mathjax.rstudio.com/latest/MathJax.js?config=TeX-MML-AM_CHTML";
    if (location.protocol !== "file:")
      if (/^https?:/.test(src))
        src = src.replace(/^https?:/, '');
    script.src = src;
    document.getElementsByTagName("head")[0].appendChild(script);
  })();
</script>
</body>

</html>
